A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Ronald B. Gartenhaus, M.D.
Professor of Medicine

Department:
University of Maryland Greenebaum Cancer Center

UMGCC Research Program:
Molecular and Structural Biology Program

Education/Training:
College Degree: B.A., University at Albany
Medical Degree: M.D.
Residency: Internal Medicine
University Hospital
State University of New York at Stony Brook
Fellowship: Fellowship in Medical Oncology
M.D. Anderson Hospital and Tumor Institute
IRTA Fellow
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Laboratory of Tumor Cell Biology
Certification: Diplomate, American Board of Internal Medicine
Board Certified in Medical Oncology

Contact Information:

Mailing Address: 655 West Baltimore Street
Room 9-011, Bressler Research Building
Baltimore, Maryland 21201
Email: rgartenhaus@som.umaryland.edu
Phone: 410-328-3691
Fax: 410-328-6559

Research Interests:
A major focus of my research program is on the molecular etiology of lymphoid malignancies. We recently cloned and identified a novel oncogene, MCT-1, found to be amplified in a human lymphoma and that appears to have a cell cycle regulatory role as well as anti-apoptotic activity. We subsequently identified a subset of primary diffuse large B-cell lymphomas (DLBCL) that exhibited significantly elevated levels of MCT-1 protein compared with normal lymphoid tissue.

The molecular mechanism(s) underlying the activity of MCT-1 are currently being investigated in the laboratory. MCT-1 has been shown to contain a PUA domain that recently has been demonstrated to mediate RNA binding activity. We found that MCT-1 is a novel cap-binding protein that enhances translation of select cancer related mRNAs through its association with DENR, a molecule containing the SUI1 domain which is involved in translation initiation. The efficiency of expression of key proteins involved in cell growth regulation, proliferation or cell death may be controlled at the translational level by changes in the activity of components of the protein synthesis machinery. With the exception of eIF4E, there are few other examples of oncogenic translation factors whose aberrant expression has been shown to induce malignant transformation of cells. We have recently established a Eu-MCT-1 transgenic mouse which will provide a useful in-vivo model to study the effects of enhanced translation of MCT-1 on lymphomagenesis. Our data provides a putative mechanism underlying the development and progression of tumors associated with dysregulation of MCT-1, and further supports the linkage between translational control and oncogenesis.




Publications:
Krystyna Mazan-Mamczarz, Patrick R. Hagner, Sharon Corl, William H. Wood, Kevin G. Becker, Myriam Gorospe, Jack D. Keene, Anait S. Levenson and Ronald B. Gartenhaus: Post-transcriptional gene regulation by HuR leads to a more tumorigenic phenotype. Oncogene Oct 16;27(47):6151-63, 2008

Krystyna Mazan-Mamczarz, Patrick Hagner, Bojie Dai, Sharon Corl, Zhenqui Liu and Ron B. Gartenhaus: Targeted Suppression of MCT-1 Attenuates the Malignant Phenotype Through a Translational Mechanism. Leukemia Research Mar;33(3):474-82, 2008

Krystyna Mazan-Mamczarz, Patrick R. Hagner, William H. Wood, Yongqing Zhang, Kevin G. Becker, Zhenqui Liu and Ronald B. Gartenhaus: Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Research Oct 1;68(19):7730-5, 2008

Zhenqui Liu, Ronald B Gartenhaus, Ming Tan and Xiaoli Jiao: Gene and Pathway Identification with Lp Regularized Bayesian Logistic Regression. BMC Bioinformatics, Oct 3;9:412, 2008

Patrick Hagner, Krystyna Mazan-Mamczarz, Bojie Dai, Sharon Corl, Zhenqui Liu and Ronald B. Gartenhaus: Alcohol Consumption and Decreased Risk of NHL: Role of mTOR Dysfunction. Blood, May 28;113(22):5526-35, 2009

Xianfeng Frank Zhao and Ronald B. Gartenhaus. Phospho-p70S6K and cdc2/cdk1 as Therapeutic Targets for Diffuse Large B-cell Lymphoma. Expert Opinion on Therapeutic Targets, Sep;13(9):1085-93.2009

Bojie Dai, Patrick Hagner, X. Frank Zhao, Paul Shapiro, Krystyna Mazan-Mamczarz, Shuchun Zhao, Yasodha Natkunam, and Ronald B. Gartenhaus. ERK Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. Cancer Res, October 1; 69: (19). 2009

Patrick Hagner, Abraham Schneider, and Ronald B. Gartenhaus. Targeting the Cellular Translational Machinery as a Novel Treatment Strategy for Hematologic Malignancies. Blood, March 18; 115(11): 2127 - 2135. 2010

Abraham Schneider, and Ronald B. Gartenhaus. AMPK Signaling: A Targetable Tumor Suppressor Pathway? Cancer Biology & Therapy, Dec 11;10(11). 2010

Hagner PR. Mazan-Mamczarz K, Dai B, Gartenhaus RB. Ribosomal protein S6 is highly expressed in non-Hodgkins lymphoma and associates with mRNA containing a 5 terminal oligopyrimidine tract. Oncogene, Nov 22. [Epub ahead of print] 2010

Krystyna Mazan-Mamczarz; Patrick R Hagner; Yongqing Zhang; Bojie Dai; William HWood; Kevin G Becker; Jack D Keene; Myriam Gorospe; Zhenqui Liu; Ronald Benjamin Gartenhaus. ATM regulates a DNA damage response post-transcriptional RNA operon in lymphocytes. Blood, Feb 24;117(8):2441-50. 2011

Savita Bhalla, Andrew M. Evens, Bojie Dai, Sheila Prachand, Rebecca Elstrom, Leo I. Gordon, and Ronald B. Gartenhaus. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood May 31. [Epub ahead of print] 2011

Bojie Dai, X. Frank Zhao, Krystyna Mazan-Mamczarz, Patrick Hagner, Sharon Corl, El Mustapha Bahassi, Peter J Stambrook, Paul Shapiro and Ronald B. Gartenhaus. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nature Communication, in press